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Discovery of a Small Molecule that Inhibits
the Interaction of Anthrax Edema Factor
with Its Cellular Activator, Calmodulin
these binding pockets and make extensive contacts to
the protein. The development of small molecules that
inhibit protein-protein complexes, by contrast, does not
benefit from previously characterized “lead” com-
pounds. Further, the relatively flat surface of a protein
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been discovered through screening of diverse chemical
libraries. Recent examples of IPPIs have served as im-
portant reagents for dissecting complex cellular pro-Summary
cesses [2–6].
The interaction between Bacillus anthracis EF andThe catalytic efficiency of adenylyl cyclase activity of
edema factor (EF) from Bacillus anthracis is enhanced CaM provides an appealing target for the development
of an IPPI. B. anthracis, or anthrax, secretes severalby approximately 1000-fold upon its binding to mam-
malian protein calmodulin (CaM). A tandem cell-based proteins relevant to the anthrax pathology. EF is a se-
creted protein that possesses Ca2/CaM-dependentand protein binding-based screen of a 10,000 member
library identified a molecule that inhibits the EF-CaM adenylyl cyclase activity. Lethal factor (LF) is a metallo-
protease, and protective antigen (PA) helps the deliveryinteraction and therefore the adenylyl cyclase activity.
A combination of fluorescence spectroscopy and photo- of EF and LF into target cells. According to currently
accepted models (for a review, see [7]), secreted PAlabeling studies showed that the molecule targets the
CaM binding region of EF. A series of related compounds first binds to a cellular anthrax receptor and undergoes
proteolysis by furin [8]. The proteolyzed product of PAwere synthesized and evaluated to identify one com-
pound, 4-[4-(4-nitrophenyl)-thiazolylamino]-benzene- oligomerizes on the cell surface, providing binding sites
for EF and LF. Following receptor-mediated endocyto-sulfonamide, that maintained activity against EF but
showed minimal toxicity to two cultured cell lines. This sis, conformational changes of PA induce the release
of EF and LF into the cytosol, where EF forms a complexcompound represents an important reagent to study
the role of EF in anthrax pathology and may represent with cellular CaM. This EF-CaM complex catalyzes the
conversion of ATP to a second messenger, cAMP. Thea drug lead against anthrax infection.
complex of EF-CaM is approximately 1000-fold more
active than is EF alone [9, 10], providing a strategy toIntroduction
activate the adenylyl cyclase activity in the host cell.
Therefore, by interrupting the EF-CaM interaction withThe association of proteins plays a role in all cellular
processes. Protein-protein interactions serve to orga- a small molecule, the pathological effects of EF may be
reduced significantly.nize and maintain the cytoskeletal structure in the cell,
modulate enzymatic activities, and localize enzymes The recently solved crystal structure of the EF-CaM
complex reveals that the protein-protein interaction isand substrates at discrete positions in the cell. For these
reasons, the discovery of small molecules that inhibit quite distinct from other CaM binding proteins [9, 11].
The structures of several complexes of CaM with CaMprotein-protein interactions is a goal of many research
programs that seek inhibitors for use as reagents in cell binding proteins reveal that the central  helix of CaM
is kinked and wrapped around the -helical CaM bindingbiology and as therapeutics in medicine. This paper
reports a strategy that combines cell-based screening domains [11]. However, in the structure of the EF-CaM
complex, the central  helix of CaM adopts an extendedwith protein interaction screening to identify a small
conformation surrounded by two domains of EF [9, 10].molecule that inhibits the activation of edema factor by
For this reason, a small molecule that binds to the CaMcalmodulin in cells.
binding region of EF may not interfere with the manyThe identification, or design, of small molecules that
other important roles of CaM in cells.inhibit protein-protein interactions is substantially more
To identify a small molecule that inhibits the EF-CaMdifficult than is the development of inhibitors targeting
interaction, we screened a library containing 10,000 di-enzyme active sites or ligand binding pockets [1]. For
verse structures using a combination of a cell-basedthe latter case, the availability of natural ligands and
assay and a surface plasmon resonance (SPR) spectros-substrates provides a good starting point for developing
copy-based protein-protein binding assay. This screeninhibitors. Furthermore, active sites of enzymes and li-
identified one compound as an inhibitor of the EF-CaMgand binding pockets of receptors are intrinsically
complex. In vitro assays showed that the compoundmatched for binding of small molecules, which can fill
targets EF and inhibits the catalytic activity of EF by
disrupting the EF-CaM interaction. This initial hit was*Correspondence: mmrksich@uchicago.edu (M.M.); wtang@
toxic to cultured mammalian cells at concentrationsuchicago.edu (W.-J.T)
4These authors contributed equally to this work. above the IC50. We therefore synthesized a series of
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Figure 1. Identification of an Inhibitor that
Blocks the Interaction of EF and CaM
(A) A cell-based assay reports on ET-induced
morphological changes in Y1 cells. Cells were
treated with control medium (left), ET (EF [5
ng/ml]), and PA (25 ng/ml) (middle) or
ET10506-2A (EF [5 ng/ml]), PA (25 ng/ml)
and 10506-2A (10 M) (right).
(B) SPR assays were used to identify a com-
pound, 10506-2A, which acts by inhibiting the
binding of EF and CaM. EF (0.8 M) was
mixed with 10506-2A (1% DMSO) and al-
lowed to interact with cutinase-CaM immobi-
lized on the surface for 15 min.
(C) Chemical structure of 10506-2A.
structurally related compounds and identified one that specifically by interacting with large numbers of proteins
[16]. To exclude compounds that inhibit EF by nonspe-retains inhibitory activity, but with a reduced toxicity to
cific mechanisms, we tested each of these compoundscultured mammalian cell lines.
for inhibition of two unrelated enzymes: -lactamase
and -chymotrypsin. Three of the twenty-seven com-Results
pounds inhibited these unrelated enzymes at a low mi-
cromolar range and were excluded from further study.Screening Strategy
The remaining 24 compounds were then individuallyTo identify candidate inhibitors of EF, we first screened
tested using an SPR-based assay to identify moleculesa library of molecules in a cell-based assay. We started
that act by blocking the association of EF with immobi-with this assay because our ultimate goal was to identify
lized CaM (Figure 1B). We have previously developed acompounds that were active in cell culture. The assay
cutinase-directed method for covalent immobilizationreports on a cAMP-triggered morphological change in
of functional proteins on self-assembled monolayersY1 cells, a cultured line of murine adrenocortical cells
[15] and showed that this strategy is useful for quantita-(Figure 1A) [12]. The addition of edema toxin (ET; a com-
tive analysis of the EF-CaM interaction [14]. This methodbination of EF and PA) to Y1 cells leads to an increase in
allows immobilization of the CaM protein with a definedthe level of intracellular cAMP, with downstream effects
density and orientation, and provides a higher activitythat include the dephosphorylation of paxillin and a loss
of the protein than do other immobilization methodsof focal adhesions [13], leading to a distinct morphologi-
that result in random attachment and denaturation ofcal change in cells from flat/spread to round (Figure 1A).
proteins [17]. Furthermore, the monolayers present oligoCompounds that blocked the EF-induced morphology
(ethylene glycol) groups that reduce the nonspecific ad-changes in Y1 cells were then evaluated in a surface
sorption of EF [18]. Of the 24 compounds identifiedplasmon resonance (SPR) spectroscopy-based assay
above, we found that 1 compound (4-[4-(3,4-dichloro-to identify the subset of compounds that act by pre-
phenyl)-thiazolylamino]-benzenesulfonamide) (10506-2A;venting the association of EF and CaM [14, 15].
Figure 1C) efficiently inhibited the binding of EF to immo-
bilized CaM in a dose-dependent manner with an IC50Identification of an Inhibitor of 10 M (Figure 2A).
of the EF-CaM Interaction We next confirmed that 10506-2A inhibits the adenylyl
We first employed the Y1 cell-based assay to screen cyclase activity of EF3, a recombinant protein containing
the 10,000 compound library in pools of eight in dupli- the catalytic domain of EF, in the presence of CaM (0.5
cate. We found that approximately 20% of the pools M). A dose-dependence study revealed that 10506-2A
showed precipitation, visible cell death, or unrelated inhibits the activity of EF with an IC50 of 10–15 M. This
morphological changes in the absence of toxins: com- value agrees with the activity found in the SPR assays of
pounds in these pools were not analyzed in subsequent protein-protein binding (Figure 2B). Finally, dose-depen-
experiments. These pools may contain a few potentially dent assays with cultured Y1 cells showed that 10506-2A
active compounds, but because we identified enough inhibits the ET-induced morphological change at concen-
active compounds as described below, we decided not trations of 15 M or higher (Figure 2C). Taken together,
to retest compounds in the precipitated pools. We found these results establish that the catalytic activity of EF can
that approximately 30 pools of compounds inhibited the be inhibited by blocking its interaction with CaM.
morphological changes induced by ET. We individually
screened each of the 240 molecules in the active pools 10506-2A Binds EF to Prevent the Activation
and identified 27 compounds as initial hits (see Supple- of EF by CaM
mental Data). It has been reported that some com- To gain insight into the mechanism by which 10506-2A
disrupts the interaction of EF and CaM, we examinedpounds identified as IPPIs in cell-based assays act non-
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Figure 2. Quantitative Analysis of EF Inhibi-
tion by 10506-2A
(A) Dose-dependent inhibition of the binding
of EF to immobilized CaM was determined
by SPR experiments. The amount of EF that
bound to the immobilized CaM is plotted for
several concentrations of 10506-2A, where
each measurement is the average of three
determinations and the standard deviation is
given by the error bar.
(B) Dose-dependent inhibition of adenylyl cy-
clase activity of EF was determined in a cAMP
assay. Each data point represents an average
of ten independent experiments.
(C) Morphology changes in Y1 cells treated
with EF and PA in the presence of 10506-2A
are shown. Bars represent 30 m.
the enzymatic activity of EF at several concentrations pools of the adduct to protease treatments with trypsin,
-chymotrypsin, or Arg-C. The resulting proteolytic frag-of CaM and 10506-2A (Figure 3A). The concentration of
CaM that gave one-half the maximum activity of EF (the ments were analyzed by MALDI-TOF mass spectrometry
(Figure 4B). In each of the enzymatic digestions, 70%–EC50) was approximately 100 nM. This value is slightly
higher than the reported dissociation constant (Kd) of EF 80% of the primary sequence of EF was represented in
the peptide fragments. By using three different diges-and CaM in the absence of DMSO [14]. In the presence of
10506-2A, however, the EC50 for CaM increases. For an tions, 100% of the primary sequence was represented.
We observed a correlation between several peaks thatexperiment having 10506-2A present at a concentration
of 50 M, the EC50 of CaM increased to 10 M. This were present at lower intensity in the digests of photo-
labeled protein and new peaks showing an increase offinding is consistent with a model wherein 10506-2A and
CaM compete for binding to EF, further supporting the mass of 344  2 or 366  2 Da. These mass differences
can be attributed to coupling of the analog and its so-interpretation that 10506-2A is an IPPI.
To obtain direct physical evidence for an interaction dium adduct, respectively, to EF. Analysis of the exact
masses of the peptide fragments revealed the sites ofof 10506-2A with EF, we employed fluorescence experi-
ments to probe the binding of the molecule with EF and photolabeling of the protein with the small molecule. For
tryptic digestions, peptides 631–651, 614–630, 635–651,CaM. The inhibitor has an excitation resonance at 328
nm with an associated emission at 405 nm. We acquired 654–672, 673–690, and 740–755 formed photoadducts.
For ArgC digestions, peptides 631–672 and 631–671fluorescence spectra of the compound in solutions con-
taining EF in concentrations ranging from 0.1 to 100 M. formed adducts, and for -chymotryptic digestions,
peptides 751–777 and 752–773 formed adducts. WhenThe emission band showed increasing intensity and a
hypsochromic shift with increasing concentrations of these peptides were overlaid on the three-dimensional
structures of EF alone and of the EF-CaM complex,EF [19]. Identical experiments with addition of CaM to
10506-2A, by contrast, did not produce significant all of the identified peptides mapped to the C-terminal
helical domain and the interface between the catalyticchanges in the fluorescence spectrum of 10506-2A. This
experiment provides further support for the interpre- core of EF and the helical domain (Figure 4C). Each of
the peptides was sufficiently proximal to the CaM bind-tation that 10506-2A binds to EF and not to CaM (Fig-
ure 3B). ing site to perturb CaM binding to EF. In addition to
the peptides noted above, several peptides (aa 66–88,We next performed a photolabeling experiment with
an azidophenyl analog of 10506-2A (Figure 4A) to iden- 106–137, 215–237, and 171–192) corresponding to the
PA binding domain of EF also gave photoadducts withtify the binding site of the molecule on EF. A mixture of
the photolabeling analog (50 M) and EF (10 M) was the small molecule.
irradiated with UV light (254 nm, 300 W/cm2) for 5 min.
A MALDI-TOF mass spectrum of the EF protein showed Specificity of 10506-2A
To ensure that 10506-2A does not inhibit other CaM-substantial broadening after the irradiation, with an in-
crease in the apparent average mass of 200–400 Da interacting proteins, we tested the effects of 10506-2A
on two mammalian CaM-dependent proteins and on a(Figure 4A). Analogous experiments with CaM, by con-
trast, showed no significant mass changes on irradiation secreted bacterial protein. Calcineurin, a mammalian
Ser/Thr phosphatase [20], is regulated by binding toof the protein. Addition of excess 10506-2A prevented
the photocoupling of EF by the azidophenyl analog (data CaM. We found that this interaction was not inhibited
by 10506-2A in the SPR assays (Figure 5A). Mammaliannot shown). We also used SPR experiments to verify
that the azido-photolabeling analog also inhibits the adenylyl cyclase 1 (mACI) is a transmembrane enzyme
regulated by CaM [21]. Adenylyl cyclase assays donebinding of EF to immobilized CaM with a comparable
IC50 to the parent inhibitor (data not shown). in the presence of 10506-2A showed that the inhibitor
did not have a significant effect on mACI (Figure 5B).To define the binding site, we purified the photola-
beled EF adduct with HPLC and subjected identical However, CyaA, a CaM-activated adenylyl cyclase se-
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N-phenylthiazol-2-amine, or the phenyl-thiazole moiety,
4-aminobenzenesulfonamide, were not active inhibitors.
An analog lacking the two chlorides and the sulfonamide
groups, N,4-diphenylthiazol-2-amine, was also inactive.
Taken together, these results indicate that both the ben-
zenesulfonamide and the phenylthiazole moieties are
required for the inhibitory properties of 10506-2A.
To be useful for studies in cell culture, the inhibitor
must be nontoxic to uninfected mammalian cells. When
we evaluated the toxicity of 10506-2A in Chinese ham-
ster ovary (CHO) and mouse Y1 cells using lactate dehy-
drogenase (LDH) assays, which is a stable cytosolic
protein released into the culture media on cell death,
we found that 10506-2A showed significant toxicity at
30–50 M concentrations (Figure 6A).
To obtain an inhibitor with less cytotoxicity, we syn-
thesized a series of molecules that presented different
functional groups on the phenylthiazolyl domain of 10506-
2A. One of these analogs, 4-[[4-(4-nitrophenyl)-2-thiazolyl]
amino]-benzenesulfonamide (nitro10506-2A), was nontoxic
to both CHO and Y1 cell lines (Figure 6A) while the
inhibitory effects of nitro10506-2A were similar to those
of 10506-2A in both enzyme activity and CaM binding
assays (Figures 6B and 6C). The Y1 cell-based assay
(Figure 6D) also showed that nitro10506-2A inhibited
morphological changes at 12 M. Finally, we monitored
the effect of nitro 10506-2A on the intracellular cAMP
level in CHO cells (Figure 6E). We found that nitro 10506-
2A did prevent the increase of intracellular cAMP in-
duced by edema toxin (EFPA) without altering the
basal cAMP level (PA alone). Nitro10506-2A represents
the best inhibitor found in the current study.
Figure 3. Mechanism of Inhibition Discussion
(A) Activation of EF by CaM is inhibited by 10506-2A. EF (1 nM) was
mixed with variable amounts of 10506-2A (1% DMSO) and CaM as This study reports a strategy to screen for inhibitors of
noted in the figure. The formation of cAMP in vitro was monitored protein-protein interactions (IPPIs) that are active in cell
as described in the Experimental Procedures. Each data point repre-
culture. Two considerations prompted us to begin thesents an average of at least three independent experiments.
screen with a cell-based assay. First, the Y1 cellular(B) Fluorescence titration of 10506-2A in the presence of EF3 or
CaM. To determine the molecular target of 10506-2A, fluorescence assay, which reports a readily identifiable phenotypic
emission spectral changes of 10506-2A in the presence of EF or response, is simple and readily adapted to a high-
CaM were monitored. Intrinsic fluorescence emission spectra of throughput format. The protein-protein binding assay
10506-2A shifts from 370 to 405 nm in the presence of EF, but not that we use is based on SPR and, in contrast, is not
in the presence of CaM. Each data point represents an average of
compatible with a high-throughput format. Second, ourat least three independent experiments.
goal in this work was to identify compounds for use in
cell culture. The cell-based assays are required for this
purpose because many compounds found in screenscreted by B. pertussis, was inhibited by 10506-2A. CyaA
has a catalytic domain similar to EF and was reported of protein-protein binding interactions have undesirable
transport, stability, or cytotoxicity to be effective in cellto interact with CaM in a similar manner [22].
culture. Therefore, in cases where the molecular assay—
that is, the assay that measures protein-protein bindingStructure-Function Relationships Identify
an Inhibitor with Minimal Toxicity interactions—is not suited to rapid and parallel screen-
ing, it can be preferable to begin with a simple cellularTo define minimal features required for the inhibition of
EF, we synthesized several analogs of 10506-2A and assay to give a small number of candidate inhibitors.
These compounds can then be characterized in molecu-evaluated the activities in the SPR binding assay (Figure
5C). The first compound, [(4-phenyl-2-thiazolyl)-4-amino]- lar assays and further analyzed to understand the mech-
anism of action.benzenesulfonamide, lacks the two chlorides in the
right-handed phenyl ring and inhibited the binding of A common and very powerful format for screening
molecules in cell-based assays relies on the yeast two-EF to CaM with an IC50 value similar to 10506-2A. This
compound also inhibited the adenylyl cyclase activity hybrid method [23]. This method has been particularly
important in screens of molecules that disrupt protein-of EF (data not shown). Compounds lacking the sulfon-
amide moiety of the original hit, 4-(3,4-dichlorophenyl)- protein interactions. In this case, however, substitution
A Calmodulin Binding Blocker of Anthrax EF
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Figure 4. Characterization of the Binding of 10506-2A to EF by Photocrosslinking
(A) Mass spectrometric analysis of CaM, EF3, and EF with and without photocrosslinking of 10506-2A. Each protein (1 mg/ml) was mixed
with azido10506-2A (100 M, 1% DMSO; shown in [A]) and irradiated under UV light. The molecular weight changes of the proteins were
measured with MALDI-TOF mass spectrometry to determine the molecular target of 10506-2A. Mass spectrometry of proteins with and without
azido10506-2 are shown in red and black, respectively.
(B) A representative result of proteolytic analysis of photocrosslinked EF. Following photocrosslinking with azido10506-2A, EF was digested
with -chymotrypsin, and the fragments were analyzed by MALDI-TOF mass spectrometry. The top panel shows the digestion pattern of
untreated EF, and the bottom panel shows the digestion pattern of photocrosslinked EF. Three peaks with reduced intensity after photocrosslink-
ing are labeled as a, b, and c while the corresponding peaks that increased in molecular weight by 344 or 366 Da (the size of azido10506-2A
or its sodium adduct, respectively) are labeled a, b, and c. Identity of each peptide was determined by comparison of computer-generated
EF-digestion pattern.
(C) The map of azido10506-2A-coupled peptides on the structure of EF3 with and without CaM. EF and CaM are shown in green and blue,
respectively. Peptides near 10506-2A binding site were determined as in Figure 4B, and their locations were noted in published EF structures.
Peptides appearing in more than one digestion are shown in red, while peptides appearing in only one digestion experiment are shown in
pink.
of the EF-CaM protein-protein complex in the transcrip- without employing fusion proteins or nuclear local-
ization.tional machinery would result in an enzymatic activity
that is toxic to host cells. Using yeast two-hybrid screens As an inhibitor of a CaM binding protein, 10506-2A is
somewhat unusual. Numerous CaM antagonists havein such a system can be complicated. In addition, the
cell-based screening method described in this manu- been developed that bind to the hydrophobic surfaces of
CaM that are exposed upon Ca2 binding [24]. However,script uses a more pathologically relevant environment
Figure 5. The Specificity of 10506-2A and Its
Analogs
(A) The effect of 10506-2A on the binding of
calcineurin to immobilized CaM was moni-
tored using SPR spectroscopy as in Figure
2A. Binding was measured with 0.3 M cal-
cineurin and varying amounts of 10506-2A.
Each data point represents an average of
three independent experiments.
(B) Effect of 10506-2A on the catalytic activity
of bacterial and mammalian adenylyl cy-
clases. Adenylyl cyclase activities of EF3,
CyaA, and mammalian adenylyl cyclase 1
(mAC1) in the presence of 50 M 10506-2A
(gray bars) were measured as in Figure 2B.
The relative adenylyl cyclase activities were
compared with the activity of each enzyme
in the presence of DMSO (black bars). Each
bar represents an average of three indepen-
dent experiments.
(C) Effects of small molecules structurally re-
lated to 10506-2A on the binding of EF3 to
CaM were monitored using SPR spectros-
copy. Binding of EF3 to immobilized CaM was
measured in the presence of analogs and 1%
DMSO as in Figure 2A. Each data point repre-




Figure 6. An Inhibitor for the EF-CaM Interac-
tion with Minimal Cytotoxicity
(A) Nitro10506-2A (closed circles) is less toxic
than is 10506-2A (open circles) in Y1 (left) and
CHO (right) cells. Toxicity of each compound
to cultured cells in the absence of EF and PA
was monitored using LDH assays as de-
scribed in the Experimental Procedures.
(B) Inhibition of EF-catalytic activity by ni-
tro10506-2A. Each data point represents an
average of three independent experiments.
(C) Inhibition of EF binding to immobilized
CaM by nitro10506-2A was monitored using
SPR spectroscopy as in Figure 2A. Each data
point represents an average of three indepen-
dent experiments.
(D) Inhibition of ET-induced cell morphologi-
cal change by nitro10506-2A was monitored
as in Figure 2C. Bars represent 30 m.
(E) Inhibition of ET-induced increases in cellu-
lar cAMP by nitro10506-2A was monitored
using cAMP-specific antibodies. A mixture of
EF (5 ng/ml) and PA (25 ng/ml) (open circles)
or PA alone (closed circles) was added to
CHO cells that had been preincubated with
nitro10506-2A. The levels of cAMP were
measured following lysis as described in the
Experimental section. Each data point repre-
sents an average of three independent exper-
iments.
these compounds have the unwanted effect that they suggest that CyaA and EF share structural features in
the CaM binding regions that are not apparent by analyz-inhibit the interactions of CaM with a large number of
target proteins. In one counter example, KN-62, a com- ing the primary sequences.
In common with many reports of chemical screening,mon inhibitor of calmodulin-dependent protein kinase
II (CaMK II), has been shown to act by binding directly we found that the inhibitor identified in the primary
screen ultimately suffered from significant cytotoxic ef-to CaMK II [25]. Unlike CaM antagonists, inhibitors such
as KN-62 or 10506-2A demonstrate considerable speci- fects on cells. We therefore established the minimal
structure-activity relationship and from this informationficity for their target protein over other CaM-activated
processes. In our study, we illustrate how three different were able to identify an analog that retained inhibitory
activity but was tolerated by cells. Our finding that aassays can be used to establish the target of inhibitors
identified in screens. Kinetic studies can reveal competi- minor structural change gave a significant reduction in
cytotoxicity suggests that the inhibitors may be furthertive binding of the small molecule for one of the protein
targets. Fluorescence studies, for small molecules that enhanced with minimal modifications.
have a strong fluorescence mode, may reveal the protein
that is bound by the inhibitor. Finally, photolabeling Significance
studies provide the strongest evidence for identifying
the site of action of a small molecule IPPI. In this paper, we have reported a screening strategy
to identify a small molecule inhibitor of the EF-CaMOur work used several assays to establish that the
10506-2A inhibitor of the EF-CaM interaction has good protein-protein complex from a diverse chemical li-
brary. Using a cell-based assay to first screen 10,000specificity. However, we found that 10506-2A is also
effective at inhibiting CyaA. Despite the significant ho- compounds resulted in the identification of several
molecules. Further characterization of these candi-mology between CyaA and EF, this finding was unex-
pected because the CaM binding domains of these two dates in a SPR protein-protein binding assay revealed
that only one of these compounds acted through spe-proteins share only limited homology. This result may
A Calmodulin Binding Blocker of Anthrax EF
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sis of -chymotrypsin were measured using N-benzoyl-L-tyrosine-cific inhibition of the EF-CaM complex. Therefore, this
p-nitroanilide as a substrate. 0.8 M -chymotrypsin was incubatedresult represents an important addition to the modest
with 10506-2A for 5 min at 25C in the same buffer used for SPRnumber of IPPIs reported to date. We believe that the
experiments and 1.0% (v/v) DMSO. To this mixture, N-benzoyl-L-
screening strategy described here—cell-based assays tyrosine-p-nitroanilide in DMSO was added to a final concentration
to narrow the number of candidates followed by pro- of 250 M. Final DMSO concentrations in assays were 5% (v/v).
The hydrolysis reaction was followed at 25C for 5 min at 405 nmtein binding assays to identify IPPIs—will find wider
with a Beckman DU-640 spectrophotometer.use for identifying IPPIs of other protein-protein inter-
actions, provided that a convenient cell-based assay
is available. The small molecule inhibitor of the EF- Quantitation of Toxicity and Cellular cAMP Concentrations
CaM interaction will complement active site targeting Toxicity of 10506-2A was evaluated using the CytoTox 96 kit from
Promega Corp. (Madison, WI) as described in manufacturer’s in-inhibitors of EF [26, 27] and will be a useful tool in
struction. In brief, Y1 cells were plated at 1.5  105 or 3  105 cells/cellular studies of anthrax toxins and a valuable lead
ml and 10506-2A was applied the following day as described abovetoward anthrax therapeutics. (For recent examples of
and incubated for 1 hr. Membrane breakdown was assessed by thesmall molecules that target the active site of EF-CaM,
amount of tetrazolium salt converted to a formazan product by lactate
see [26, 27]). dehydrogenase, detected by reading the absorbance at 490 nm.
Production of cAMP was determined by using Direct Cyclic AMP
Experimental Procedures Enzyme Immunosassy Kit from Assay Designs, Inc. (Ann Arbor, MI).
CHO cells were seeded in a 48-well plate at 1.5  105 cells/well and
Chemical Library incubated for 24 hr. Nitro10506-2A compound was applied with final
The chemical library of 10,000 compounds (Library No. ET 350-1) concentrations ranging from 3.1 to 100 M and incubated for 1 hr
was purchased from ChemBridge (San Diego, CA). Averages and at 37C. EF (5 ng/ml) and PA (25 ng/ml) mix was added followed by
standard deviations of clogP and molecular weight are 3.7  1.5 2 hr incubation at 37C. Following lysis with 0.1 N HCl. Concentra-
and 340  71, respectively. tions of cAMP were assessed at 405 nm as described in manufactur-
er’s instruction.
Cell Cultures and Morphological Assay in Y1 Cells
Y1 cells were maintained at 37C with 5% CO2 in Dulbecco’s modi-
Fluorescence Spectroscopyfied Eagles medium (DMEM) supplemented with 2.5% (v/v) fetal
Fluorescence emission spectra were obtained using Fluoromax 3bovine serum (FBS) and 12.5% (v/v) horse serum. CHO cells were
with a temperature controller at the Biophysics Core Facilities (Uni-grown in DMEM/F-12 with 10% heat-inactivated FBS. Plates and
versity of Chicago). All experiments were performed at 25C. 0.5 Mflasks were coated with 1% gelatin before cells were plated to
10506-2A in the same buffer used in SPR experiments, 1% (v/v)facilitate cell attachment and spreading. Y1 cells were plated in 96-
DMSO, and EF3 or CaM was excited at 328 nm (slit width 5 nm),well plates at 200 l/well and used when they reached 50%–80%
and emission spectra were collected. The ratios of intensities at 370confluence. The chemical library was assayed by preparing solu-
and 405 nm were plotted against protein concentrations.tions containing eight compounds in DMSO (5 mg/ml each) and
adding 2 l of each solution to two wells of Y1 cells. After 1 hr
incubation, EF and PA were added (5 and 25 ng/ml final concentra-
Synthesis of 4-[4-(4-Nitrophenyl)-Thiazolylamino]-tions, respectively) and the morphology of Y1 cells was examined
Benzenesulfonamide and Related Compounds1, 4 hr, and overnight after the addition of toxin. Effective pools
Syntheses of 4-[4-(4-nitrophenyl)-thiazolylamino]-benzenesul-were identified and compounds in these pools were individually
fonamide was performed according to a reported route for an analo-screened so that the active compound could be identified. Active
gous compound [29]. Briefly, an aqueous solution (100 ml) ofcompounds were then examined at final concentrations ranging
4-thioureidobenzenesulfonamide (1.20 g, 4 mmol) was combinedfrom 1.56 to 50–100 M.
with 4-nitrophenacyl bromide (1.1 equivalents) in ethanol (10 ml).
The mixture was refluxed for 2 hr, allowed to cool, and filtered. The
Surface Plasmon Resonance Spectroscopy product was isolated from a recrystallization in ethanol. 1H-NMR
Surface plasmon resonance (SPR) was used to monitor the binding (400 MHz; DMSO-d6): 7.99(d, J 	 8.5 Hz, 2H), 7.82 (m, 4H), 7.43 (s,
of EF to CaM and to characterize small molecule inhibitors as de- 1H), 7.19 (d, J	 8.5 Hz, 2H); m/z (APCI, negative ion mode detection):
scribed previously [14, 15, 27]. In brief, 0.8 M EF in a solution 375.0 [M-H]
 and 410.9 [M·Cl]
. Other analogs were synthesized in
containing 10 mM Tris-HCl, pH 7.0, 1.0 mM EGTA, 10 mM MgCl2, the same manner using appropriate 2-bromoacetophenone deriva-
100 mM KCl, and 0.96 mM CaCl2 was mixed with inhibitors in DMSO tives.
(1% v/v). The mixture was then flowed over the immobilized CaM
[14, 15] at a flow rate of 3 l/min for 15 min. The amount of bound
EF was determined from the response change following 10 min Photocrosslinking and Mass Spectrometry
washing with the protein-free buffer. The surface was regenerated 4-[[4-(4-azidophenyl)-2-thiazolyl]amino]-benzenesulfonamide (az-
by washing the surface with 10 mM EGTA for 10 min. The effects ido10506-2A) was synthesized from 4-thioureido-benzenesulfon-
of inhibitors on calcineurin were also determined as above using amide and 4-azido-2-bromoacetophenone as described above. La-
0.3 M calcineurin. beling experiments were performed with 1 mg/ml EF or CaM in 50
l of buffer (10 mM HEPES, pH 7.5, 1% DMSO) containing az-
ido10506-2A at a concentration of 100 M. The mixture was irradi-Enzymatic Assays
Adenylyl cyclase activities were measured in the presence of 20 ated with a hand-held UV lamp (254 nm, 300 W/cm2) for 5 min.
Insoluble particles were formed and removed by centrifugation. Typ-mM HEPES (pH 7.2), 5 mM ATP with trace amounts of [32P]-ATP,
1 mM EDTA, 10 mM MgCl2, and 1 M CaCl2 for 10 min at 30C ical labeling yields were 10%–30% when analyzed using analytical
HPLC. Proteolysis reactions were done by mixing the samples withunless otherwise indicated. CaM titrations were performed in the
presence of 10 mM free Mg2, 2 M free Ca2, and 10 mM EGTA. ArgC (0.5g/ml), TLCK-treated-chymotrypsin (10g/ml), or TPCK-
treated trypsin (0.1 g/ml) at 37C for 3 hr. Digested peptides wereConcentrations of free ions were calculated using the MAXC pro-
gram (http://www.stanford.edu/cpatton/max.html). ATP and cAMP then mixed with an equal volume of sinapinic acid or 2,5-dihydrox-
ybenzoic acid (10 mg/ml in 50% acetonitrile, 0.2% trifluoroaceticwere separated by Dowex and alumina columns [21]. Sf9 cell mem-
brane containing type I adenylyl cyclase was prepared and assays acid) and analyzed using matrix-assisted laser desorption/ioniza-
tion-time of flight (MALDI-TOF) mass spectrometry. Peaks werewere performed as described [28]. DMSO was limited to 1% v/v to
avoid inhibition of cyclases. Kinetic measurements of -lactamase assigned using Peptidemass (http://us.expasy.org/tools/peptide-
mass.html) allowing for one to two missed cuts.were performed as described [16]. Effects of 10506-2A on the cataly-
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